Introduction to the functions and uses of filgotinib

Filgotinib (Filgotinib), trade name Jyseleca, is a Janus kinase (JAK) inhibitor that has attracted much attention in recent years. It is mainly used in the treatment of autoimmune diseases such as rheumatoid arthritis (RA) and ulcerative colitis (UC). The drug was first approved for marketing in Europe, the United Kingdom and Japan in 2020. As a new type of targeted small molecule oral drug, filgotinib has shown good efficacy and tolerability in immunomodulation, and has received widespread attention from the international rheumatology and gastroenterology communities.

Figotinib is a selective JAK1 inhibitor. It regulates cytokine signaling and reduces immune-mediated inflammatory responses by inhibiting JAK1 protein activity in the signal transducer and activator of transcription (JAK-STAT) pathway. Compared with early broad-spectrum JAK inhibitors such as tofacitinib, filgotinib is more precise in target selectivity and can theoretically reduce interference with other subtypes such as JAK2 and JAK3 and reduce the risk of some systemic side effects. Its pharmacological mechanism makes it show good application prospects in the treatment of chronic inflammatory diseases, especially when patients have poor response or intolerance to traditional DMARDs (disease-modifying anti-rheumatic drugs), providing a valuable clinical alternative.

In terms of indications, filgotinib is currently mainly approved for the treatment of moderately to severely active rheumatoid arthritis (RA) and moderate to severe ulcerative colitis (UC). For patients with rheumatoid arthritis, when the treatment effect of methotrexate (MTX) or other traditional DMARDs is not satisfactory or the patient is intolerant, filgotinib can be used alone or in combination with other DMARDs to help relieve symptoms such as joint pain, swelling and limited activity. For ulcerative colitis, filgotinib is suitable for patients who have an inadequate response to corticosteroids or biologics, and has shown good results in both induction and maintenance phases.

Regarding usage and dosage, filgotinib has a relatively flexible dosage adjustment strategy based on different indications and individual patient differences. In the treatment of rheumatoid arthritis, the standard dose is 200 mg orally once daily. For patients with increased risks of venous thrombotic events (VTE), major cardiovascular events (MACE), or malignant tumors, the recommended starting dose is 100 mg daily, and whether the dose needs to be increased based on disease control will be evaluated. Similarly, in the induction treatment of ulcerative colitis, it is recommended to use 200 mg once a day for 10 weeks. If the clinical response is insufficient, it can be extended for a further 12 weeks; the maintenance period is also 200 mg daily, and it can be adjusted to 100 mg for special groups. Overall, long-term treatment should in principle be maintained at the lowest effective dose to balance efficacy and safety.

It is worth noting that the side effects of filgotinib are reduced compared with the early JAK inhibitors, but we still need to be alert to the risk of infection, abnormal hematological indicators, elevated liver enzymes and possible cardiovascular risks. Therefore, during use, doctors need to conduct regular monitoring and dosage adjustments based on the patient's basic medical history, medication history, and risk assessment. In addition, the potential impact of filgotinib on male fertility is still under further study, and patients with fertility plans also need to pay special attention.

Currently, filgotinib has not yet been launched in mainland China. If domestic patients want to obtain the drug, they still need to rely on overseas drug purchase channels or wait for its official approval. As the application of JAK inhibitors in the treatment of rheumatic immune diseases continues to deepen, filgotinib is expected to become an important drug option for the domestic treatment of RA and UC in the future due to its targeting advantages and clinical performance.

Reference materials:https://go.drugbank.com/drugs/DB14845